Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Orphan drug save search
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
VINC | $0.8475 -5.83% -6.19% 350K
|
|
| O: 8.68%
H: 8.37%
C: 3.66%
treatment europe drug orphan drug t-cell designation pharma
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
VIRX | $0.88 -3.19% -3.3% 53K
|
Manufacturing
|
| O: 3.57%
H: 4.21%
C: -12.45%
treatment fda drug granted therapeutics orphan drug positive t-cell designation
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
Published: 2021-11-19 (Crawled : 12:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: 21.78%
H: 4.25%
C: -19.25%
gc012 treatment fda orphan drug therapy car-t biotech drug iot granted t-cell designation
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ALVR | $0.7505 1.13% 1.12% 340K
|
Health Technology
|
| O: 6.01%
H: 0.0%
C: -13.5%
treatment fda orphan drug therapy drug t-cell tollovir designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.